NEW YORK, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
TG Therapeutics, Inc. (NASDAQCM: TGTX)
Class Period: June 4, 2018 - September 25, 2018
Lead Plaintiff Deadline: December 3, 2018
Join the action: https://www.zlk.com/pslra-1/tg-therapeutics-inc-loss-form?wire=3
Allegations: TG Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) TG was involved in cleaning the data collected in the UNITY-CLL Trial; and as a result, was able to gain an understanding as to the efficacy of the combination therapy; (2) as a result of that data cleaning, TG knew the UNITY-CLL Trial had failed to meet its stated goal and as a result, the Company would not be able to seek accelerated approval; and (3) given that the UNITY-CLL Trial had failed to meet its stated goal, it was highly unlikely that the combination therapy would meet its primary endpoint of increased progression free survival.
To learn more about the TG Therapeutics, Inc. class action contact jlevi@levikorsinsky.com.
Hasbro, Inc. (NASDAQGS: HAS)
Class Period: April 24, 2017 - October 23, 2017
Lead Plaintiff Deadline: November 27, 2018
Join the action: https://www.zlk.com/pslra-1/hasbro-inc-loss-form?wire=3
Allegations: Hasbro, Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (1) Hasbro’s relationship with Toys “R” Us was becoming increasingly important to Hasbro’s business, as Toys “R” Us was the primary retail brick-and-mortar toy store in the United States; (2) Toys “R” Us was in far worse financial condition than was being publicly reported and it would have to dramatically scale back its operations or file for bankruptcy and liquidate; and (3) Hasbro was experiencing significant adverse sales issues in the key markets of the United Kingdom and Brazil which were negatively impacting the Company’s efforts to grow sales in those markets.
To learn more about the Hasbro, Inc. class action contact jlevi@levikorsinsky.com.
Nektar Therapeutics (NASDAQ: NKTR)
Class Period: November 11, 2017 - October 2, 2018
Lead Plaintiff Deadline: December 31, 2018
Join the action: https://www.zlk.com/pslra-1/nektar-therapeutics-loss-form?wire=3
Allegations: Nektar Therapeutics made materially false and/or misleading statements and/or failed to disclose that: (1) prior studies which attempted to pegylate IL-2 failed; (2) the extended half-life of the Company's lead I-O candidate, NKTR-214, was unlikely to result in efficacy and created additional high-dosing safety concerns; (3) NKTR-214 was less effective than IL-2 alone; (4) the combination of NKTR-214 with nivolumab has yet to demonstrate significant positive results; and (5) as a result, Nektar’s public statements as set forth above were materially false and misleading at all relevant times.
To learn more about the Nektar Therapeutics class action contact jlevi@levikorsinsky.com.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com